Efficacy and Safety of BGG492 in the Treatment of Migraine
- Registration Number
- NCT00892203
- Lead Sponsor
- Novartis
- Brief Summary
This study will assess the efficacy and safety of BGG492 used to treat migraine pain.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 75
Inclusion Criteria
- Diagnosis of moderate to severe migraine for at least 1 year
- At least 1 migraine episode, but not more 15 migraine days per month
- Past use of triptans
- Migraine onset before 50 years of age
Exclusion Criteria
- Diagnosis of basilar, ophthalmoplegic or hemiplegic migraine.
- More than 6 non-migraine headaches per month
- Patients receiving migraine prophylaxis treatment
- Patients receiving regular treatment with psychoactive drugs
- Smokers
- Patients with a very high or low body weight Other protocol-defined inclusion/exclusion criteria may apply
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Active BGG492 - Comparator Sumatriptan - Placebo Placebo -
- Primary Outcome Measures
Name Time Method Reduction in migraine pain 2 hours
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (4)
California Clinical Trials, 1560 Chevy Chase Drive, Suite 140
πΊπΈGlendale, California, United States
California Clinical Trials, 15625 Lakewood Boulevard
πΊπΈParamount, California, United States
Novartis Investigator Site
π©πͺMunich, Germany
Novartis Investigative Site
πͺπΈBarcelona, Spain